Product Description
OBI-822 is being developed by Taiwan Hao Ding Biotechnology /United Asia Pharmaceutical /Yuli /Shanghai Baili Jiasheng Pharmaceutical Technology for the treatment of triple negative breast cnacner. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03562637?term=OBI-822&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Obi Pharma Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, China, Hong Kong, Korea, Mexico, Peru, Poland, Russia, South Africa, Taiwan, Ukraine, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Triple Negative Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2018-001438-16 |
GLORIA | P3 |
Active, not recruiting |
Triple Negative Breast Cancer |
2028-05-11 |
|||
2023-508755-39-00 |
OBI-822-011 | P3 |
Active, not recruiting |
Triple Negative Breast Cancer |
2025-12-31 |
2025-05-02 |
Treatments |
|
NCT03562637 |
The GLORIA Study | P3 |
Active, not recruiting |
Triple Negative Breast Cancer |
2025-12-30 |
2025-05-10 |
Patient Enrollment|Primary Endpoints|Trial Status |